E. Acuña-Cruz

Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy.

CD84 Expression Across Disease Stages and Leukemic Subpopulations in Acute Myeloid Leukemia

Simple Summary Acute myeloid leukemia (AML) remains a challenging disease, and new therapeutic targets are needed to improve patient outcomes. CD84 has recently emerged as a promising target for immunotherapeutic approaches, including CAR T-cell therapy. In this study, we evaluated CD84 expression in samples from adult...